HEALTH

Study: Aspirin may block tumor growth in certain patients with colorectal cancer

BY Michael Johnsen

 BIRMINGHAM, Ala. — Aspirin has the potential to block tumor growth in certain patients with colorectal cancer, according to an editorial in the Oct. 25, 2012 issue of the New England Journal of Medicine by a University of Alabama at Birmingham oncologist. In a study that appears in the same issue, researchers examined the use of aspirin in the treatment outcomes of patients with colorectal cancer.

Researchers collected experimental data from 964 patients with colorectal cancer, separating them into two groups based on the presence or absence of a mutation within the PIK3CA gene. The authors found that the use of aspirin after diagnosis in patients with the gene mutation was associated with a 46% reduction in overall mortality and an 82% reduction in colorectal cancer-specific mortality. In contrast, aspirin use in patients without the mutation did not affect either overall or colorectal-specific mortality.

“Approximately 17% of patients with colorectal cancer have a tumor that carries a mutated PIK3CA gene,” stated Boris Pasche, director of the UAB Division of Hematology and Oncology. “Hence, more than one in every six patients with locally advanced colorectal cancer may benefit from this therapy," he wrote. “We haven’t reached the point where we can make a big leap and advise patients to take aspirin to prevent cancer recurrence after surgery, but we are accumulating more information that helps us understand the role that aspirin can potentially play in cancer.”

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

HEALTH

Leosons Overseas acquires N’Ice, Fiberall brands from Insight Pharmaceuticals

BY Michael Johnsen

ALBANY — Leosons Overseas on Tuesday announced the acquisition of the brands N’Ice and Fiberall from Insight Pharmaceuticals. Terms of the transaction were not disclosed. 

"We are proud of our growth and success of these brands, and we feel that this acquisition will further our mission to deliver the best U.S.-made products globally," said John Ohanian, general manager and president of Leosons. "The acquisition … will broaden our existing sales and distribution reach, as well as bring scale to our business.” 

N’Ice lozenges serve as an oral anesthetic and cough suppressant, while Fiberall is a psyllium husk-based, bulk-forming laxative and fiber supplement.

 

 

 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

HEALTH

StoreBoard program sets up in-store hand-sanitizer kiosks for Duane Reade customers

BY Melissa Valliant

StoreBoard Media — a company that places advertising billboards on the security pedestals at the entrance of chain stores nationwide — is launching its StoreBoard Wellness Program throughout New York’s 259 Duane Reade stores.

Through the program, Duane Reade stores will feature StoreBoard Media’s billboards and in-store kiosks advertising brands like Eau Thermale Avene — a hypoallergenic skin recovery cream from Pierre Fabre USA — and encouraging customers to use the Purell hand sanitizer at the kiosk.

“Consumers see drug stores like Duane Reade as the place for all their healthcare needs,” said Rick Sirvaitis, president of StoreBoard Media. “Our eye-catching, conveniently located Purell hand sanitizer kiosks demonstrate that the retailer cares about the health of their customers, who in turn welcome the kiosks as added value to their store visit.”

StoreBoard plans on expanding the program to other retail chains over the next few months.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES